Insider filings
InMed Pharmaceuticals Inc. (INM)
About InMed Pharmaceuticals Inc.
from the company's filings and listing- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Chief executive
- Eric A. Adams Chem.
- Employees
- 13
- Listed since
- May 5, 2014
- Market value
- $2.4M
- Price to earnings
- -
- Earnings per share
- $393.63
- Dividend yield
- -
Earnings
6 reported quarters · next on Sep 23, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q3 FY2026reported May 6, 2026 | -$0.69 | -$94.44 | $1.3M | n/a | EPS beatRevenue n/a |
| Q2 FY2026reported Feb 11, 2026 | -$0.51 | n/a | $1.1M | n/a | EPS n/aRevenue n/a |
| Q1 FY2026reported Nov 6, 2025 | -$0.44 | n/a | $1.3M | n/a | EPS n/aRevenue n/a |
| Q4 FY2025reported Sep 23, 2025 | $2.40 | n/a | $1.3M | $1.8M | EPS n/aRevenue miss |
| Q3 FY2025reported May 12, 2025 | -$1.94 | n/a | $1.2M | $1.5M | EPS n/aRevenue miss |
| Q2 FY2025reported Feb 12, 2025 | -$3.64 | n/a | $1.2M | $1.1M | EPS n/aRevenue beat |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for 2025 · proxy filed Nov 3, 2025| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Eric A. AdamsPresident, Chief Executive Officer and Director | $302K | $0 | $95K | $397K |
| Michael WoudenbergChief Operating Officer | $279K | $0 | $68K | $347K |
| Eric HsuSenior Vice President, Preclinical Research & Developm | $268K | $0 | $56K | $324K |
| Netta JagpalChief Financial Officer | $243K | $0 | $61K | $304K |
The summary compensation table from the 2025 proxy statement, current executives only. Read the filing
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Open-market insider trades
20 filings of 186 on record| Insider | Action | Shares | Price | Value | Trade date | Delay |
|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC10% owner | Bought | 1,000 | $1.55 | $2K | Jul 15, 2026 | 2d |
| Vivo Opportunity, LLC10% owner | Bought · 2 lines | 21 | $1.55 | $33 | Jul 16, 2026 | 0d |
| Vivo Opportunity, LLC10% owner | Bought · 2 lines | 15,150 | $1.55 | $23K | Jul 15, 2026 | 1d |
| Vivo Opportunity, LLC10% owner | Bought · 2 lines | 5,375 | $1.55 | $8K | Jul 14, 2026 | 2d |
| Vivo Opportunity, LLC10% owner | Bought · 2 lines | 600 | $1.54 | $924 | Jun 30, 2026 | 2d |
| Vivo Opportunity, LLC10% owner | Bought · 2 lines | 4,344 | $1.55 | $7K | Jul 1, 2026 | 1d |
| Vivo Opportunity, LLC10% owner | Bought · 2 lines | 1,607 | $1.55 | $2K | Jul 2, 2026 | 0d |
| Vivo Opportunity, LLC10% owner | Bought · 2 lines | 32,500 | $1.52 | $49K | Jun 8, 2026 | 2d |
| Vivo Opportunity, LLC10% owner | Bought · 2 lines | 17,796 | $1.57 | $28K | May 29, 2026 | 12d |
| Vivo Opportunity, LLC10% owner | Bought · 2 lines | 55,011 | $1.57 | $86K | Jun 5, 2026 | 5d |
| Vivo Opportunity, LLC10% owner | Bought · 2 lines | 22,848 | $1.52 | $35K | Jun 2, 2026 | 8d |
| Vivo Opportunity, LLC10% owner | Bought · 2 lines | 34,000 | $1.69 | $57K | May 21, 2026 | 20d |
| Vivo Opportunity, LLC10% owner | Bought · 2 lines | 6,743 | $1.57 | $11K | Jun 4, 2026 | 6d |
| Vivo Opportunity, LLC10% owner | Bought · 2 lines | 7,783 | $1.55 | $12K | Jun 3, 2026 | 7d |
| Vivo Opportunity, LLC10% owner | Bought · 2 lines | 16,336 | $1.55 | $25K | Jun 1, 2026 | 9d |
| Vivo Opportunity, LLC10% owner | Bought · 2 lines | 56,210 | $1.56 | $88K | May 20, 2026 | 21d |
| ADAR1 Capital Management, LLC10% owner | Bought · 2 lines | 268,551 | $1.52 | $409K | May 19, 2026 | 2d |
| Alexandra Diane Janet Mancini | Sold | 240 | $0.1763 | $42 | Jul 31, 2024 | 2d |
| Andrew HullDirector | Bought | 37,500 | $0.3900 | $15K | Feb 21, 2024 | 1d |
| Eric A. AdamsPresident & CEO | Bought | 41,600 | $0.3587 | $15K | Feb 20, 2024 | 1d |
One row is one filing. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count.
Awards, option exercises and gifts (20)
| Insider | Event | Shares | Date |
|---|---|---|---|
| Shane Aaron JohnsonSr VP & General Manager | Stock award | 8,500 | Dec 19, 2025 |
| Eric A. AdamsPresident & CEO | Stock award | 35,000 | Dec 19, 2025 |
| Michael WoudenbergChief Operating Officer | Stock award | 18,000 | Dec 19, 2025 |
| Eric C. HsuSr. VP, Pre-Clinical Res/Dev | Stock award | 13,000 | Dec 19, 2025 |
| John Steven BatheryDirector | Stock award | 1,750 | Dec 19, 2025 |
| Netta JagpalChief Financial Officer | Stock award | 18,000 | Dec 19, 2025 |
| Nicole LemerondDirector | Stock award | 1,750 | Dec 19, 2025 |
| Neil A. KlompasDirector | Stock award | 1,750 | Dec 19, 2025 |
| Andrew HullDirector | Stock award | 1,750 | Dec 19, 2025 |
| Andrew HullDirector | Form 4 | 14 | Dec 15, 2025 |
| Eric C. HsuSr. VP, Pre-Clinical Res/Dev | Form 4 | 70 | Dec 15, 2025 |
| Michael WoudenbergChief Operating Officer | Form 4 | 60 | Dec 15, 2025 |
| Eric A. AdamsPresident & CEO | Form 4 | 250 | Dec 15, 2025 |
| John Steven BatheryDirector | Form 4 | 3,500 | Oct 14, 2025 |
| Neil A. KlompasDirector | Stock award | 3,500 | Oct 17, 2025 |
| Andrew HullDirector | Form 4 | 2 | Jan 11, 2025 |
| Nicole LemerondDirector | Stock award | 550 | Dec 20, 2024 |
| Michael WoudenbergChief Operating Officer | Stock award | 3,750 | Dec 20, 2024 |
| Janet P. GroveDirector | Stock award | 550 | Dec 20, 2024 |
| Eric C. HsuSr. VP, Pre-Clinical Res/Dev | Stock award | 2,750 | Dec 20, 2024 |
Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.
Questions
Are insiders buying or selling INM?
Across the 20 most recent open-market filings shown here, 19 were purchases and 1 was a sale.
How quickly are INM trades disclosed?
Insider filings on this page reached the public a median of 2 days after the transaction, against the two business days Form 4 allows.
How to read a Form 4
A DECISION THE INSIDER MADE
COMPENSATION PLUMBING
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.